Skip to main content

Amoroso Michael's Form 4 filing

Precision Biosciences IncDTIL · filed Mar 25, 2025

Accession no.
0000950170-25-044599
Filed
Mar 25, 2025
Trade date
Mar 21-24, 2025
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $5.36K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Amoroso MichaelCIK 0001830874Director, Officer (President and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 21, 2025Common StockMOption exerciseAcquired+3,417–F2–110,504Direct
Mar 24, 2025Common StockSSaleDisposed−964$5.56−$5,359.84109,540Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 21, 2025Common StockMOption exerciseDisposed−3,417$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)